Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | KIF11 | P52732 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15603135 | 0.89 | EPHX2 (0.59) | EPHX2RAB9ANPC1KIF11TGM2 | |
| SCHEMBL3462701 | 0.89 | MAOB (0.61) | EPHX2RAB9ANPC1KIF11TGM2 | |
| SCHEMBL3462699 | 0.89 | MAOB (0.61) | EPHX2RAB9ANPC1KIF11TGM2 | |
| SCHEMBL15603136 | 0.89 | EPHX2 (0.59) | EPHX2RAB9ANPC1KIF11TGM2 | |
| SCHEMBL2518624 | 0.84 | EPHX2 (0.76) | EPHX2RAB9ANPC1KIF11TGM2 | |
| SCHEMBL28729179 | 0.84 | EPHX2 (1.00) | EPHX2RAB9ANPC1KIF11TGM2 | |
| SCHEMBL11003408 | 0.84 | EPHX2 (1.00) | EPHX2RAB9ANPC1KIF11TGM2 | |
| SCHEMBL11428736 | 0.83 | EPHX2 (0.68) | EPHX2RAB9ANPC1KIF11TGM2 | |
| SCHEMBL28459398 | 0.83 | EPHX2 (0.52) | EPHX2RAB9ANPC1KIF11TGM2 | |
| SCHEMBL2096237 | 0.83 | EPHX2 (0.52) | EPHX2RAB9ANPC1KIF11TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105705484-B | Carbanilate derivative as formyl peptide receptor conditioning agent | 阿勒根公司 | 2018-09-14 | — | — | CN | claimed |
| CN-105705484-A | Phenylcarbamate derivatives as formyl peptide receptor modulators | 阿勒根公司 | 2016-06-22 | — | — | CN | claimed |
| EP-1765325-A4 | 2-SUBSTITUTED HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2009-08-12 | — | — | EP | claimed |
| EP-1694658-B1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA SA (FR) | 2009-02-25 | — | — | EP | claimed |
| EP-1765325-A2 | 2-SUBSTITUTED HETEROARYL COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1694658-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | Aventis Pharma S.A. (FR) | 2006-08-30 | — | — | EP | claimed |
| WO-2006007532-A2 | 2-SUBSTITUTED HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-01-19 | — | — | WO | claimed |
| WO-2005066146-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO[3,4,5-DE][4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA S.A. (FR) | 2005-07-21 | — | — | WO | claimed |
| EP-0866793-B1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | CHIRON CORP (US) | 2004-10-27 | — | — | EP | claimed |
| EP-0923562-B1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AG (DE) | 2002-10-09 | — | — | EP | claimed |
| US-6130225-A | Substituted p-trifluoromethylphenyluracils | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | claimed |
| EP-0923562-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AG (DE) | 1999-06-23 | — | — | EP | claimed |
| WO-1998006706-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | claimed |
| JP-2598819-B2 | — | — | 1997-04-09 | — | — | JP | claimed |
| EP-0340243-B1 | CC-1065 ANALOGS | UPJOHN CO (US) | 1994-09-28 | — | — | EP | claimed |
| EP-0509795-A2 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-10-21 | — | — | EP | claimed |
| US-5118678-A | Antibody inhibitors, antiinflammatory agents, fungicides, antitumor agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-02 | — | — | US | claimed |
| EP-0340243-A1 | CC-1065 ANALOGS. | UPJOHN CO (US) | 1989-11-08 | — | — | EP | claimed |
| WO-1988004659-A2 | NOVEL CC-1065 ANALOGS | THE UPJOHN COMPANY (US) | 1988-06-30 | — | — | WO | claimed |
| US-20230227409-A1 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023101256-A1 | 5-ALPHA-REDUCTASE INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 주식회사 팜어스바이오사이언스 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023057371-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2023-04-13 | — | — | WO | disclosed |
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| WO-2022250069-A1 | SULFUR-CONTAINING PYRAZOLE COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT INCLUDING SULFUR-CONTAINING PYRAZOLE COMPOUND AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2022-12-01 | — | — | WO | disclosed |
| EP-4003983-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica International AG (CH) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174291-A | 1,2, 4-oxadiazol-5-one derivatives for the treatment of cancer | 巴斯利尔药物国际股份公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021252681-A1 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11008301-B2 | Piperidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3634955-B1 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20200207735-A1 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3634955-A1 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-107501368-B | Synthesis of doramectin derivative and insecticidal application thereof | 中国科学院成都生物研究所 | 2020-02-21 | — | — | CN | disclosed |
| US-10556889-B1 | Salvinorin derivatives | Blue Sky Pharmaceuticals, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| WO-2018227058-A1 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-13 | — | — | WO | disclosed |
| CN-105705484-B | Carbanilate derivative as formyl peptide receptor conditioning agent | 阿勒根公司 | 2018-09-14 | — | — | CN | disclosed |
| US-9926264-B2 | Phenylcarbamate derivatives as formyl peptide receptor modulators | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160272581-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| CN-105705484-A | Phenylcarbamate derivatives as formyl peptide receptor modulators | 阿勒根公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-101130526-B | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK AS | 2013-07-10 | — | — | CN | disclosed |
| WO-2011010015-A1 | PIPERIDINE COMPOUNDS, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2011-01-27 | — | — | WO | disclosed |
| EP-2277863-A1 | Piperidine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-01-26 | — | — | EP | disclosed |
| WO-2010103381-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES AS TRPM 8 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-09-16 | — | — | WO | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1694658-B1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| WO-2009009411-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| CN-101130526-A | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK AS (DK) | 2008-02-27 | — | — | CN | disclosed |
| EP-1620391-A4 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1694658-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | Aventis Pharma S.A. (FR) | 2006-08-30 | — | — | EP | disclosed |
| EP-1659121-A1 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| WO-2006043121-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-27 | — | — | WO | disclosed |
| EP-1620391-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-02-01 | — | — | EP | disclosed |
| CN-1678311-A | Arylcarbonyl derivatives useful as therapeutic agents | NOVO NORDISK AS (DK) | 2005-10-05 | — | — | CN | disclosed |
| WO-2005066146-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO[3,4,5-DE][4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA S.A. (FR) | 2005-07-21 | — | — | WO | disclosed |
| WO-2004098516-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
| US-6713468-B2 | AS ANTICONVULSANTS; FOR THERAPY AND PROPHYLAXIS OF ISCHAEMIAS, ANOXIA, NEURODEGENERATIVE DISEASES | AVENTIS PHARMA S.A. (FR) | 2004-03-30 | — | — | US | disclosed |
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | RHONE-POULENC RORER S.A. | 2003-03-20 | — | — | US | disclosed |
| EP-1000067-B1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2002-10-23 | — | — | EP | disclosed |
| US-6448241-B1 | THESE COMPOUNDS ARE ANTICONVULSANTS AND INTERFERE WITH GLUTAMATERGIC TRANSMISSION AND ARE THEREFORE USEFUL FOR THE TREATMENT OR PREVENTION OF ALL ISCHAEMIAS FOLLOWING CEREBROVASCULAR ACCIDENTS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| US-6444616-B1 | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-03 | — | — | US | disclosed |
| EP-0966473-B1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2002-07-24 | — | — | EP | disclosed |
| US-6423715-B1 | ANTICONVULSANTS | AVENTIS PHARMA S.A. (FR) | 2002-07-23 | — | — | US | disclosed |
| US-6288075-B1 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM, BRAIN, AND CARDIOVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2001-09-11 | — | — | US | disclosed |
| US-6130225-A | Substituted p-trifluoromethylphenyluracils | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | disclosed |
| EP-1025086-A1 | BENZAMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GmbH (DE) | 2000-08-09 | — | — | EP | disclosed |
| EP-1000067-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | Aventis Pharma S.A. (FR) | 2000-05-17 | — | — | EP | disclosed |
| EP-0966473-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | Aventis Pharma S.A. (FR) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999016751-A1 | BENZAMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999005147-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1999-02-04 | — | — | WO | disclosed |
| US-5866596-A | DRUGS WITH ANTIINFLAMMATORY AND ANALGESIC PROPERTIES. | LABORATORIES UPSA (FR) | 1999-02-02 | — | — | US | disclosed |
| WO-1998038194-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1998-09-03 | — | — | WO | disclosed |
| EP-0340243-B1 | CC-1065 ANALOGS | UPJOHN CO (US) | 1994-09-28 | — | — | EP | disclosed |
| US-5332837-A | Antitumor | THE UPJOHN COMPANY (US) | 1994-07-26 | — | — | US | disclosed |
| EP-0509795-A2 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-10-21 | — | — | EP | disclosed |
| US-5118678-A | Antibody inhibitors, antiinflammatory agents, fungicides, antitumor agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| EP-0340243-A1 | CC-1065 ANALOGS. | UPJOHN CO (US) | 1989-11-08 | — | — | EP | disclosed |
| WO-1988004659-A2 | NOVEL CC-1065 ANALOGS | THE UPJOHN COMPANY (US) | 1988-06-30 | — | — | WO | disclosed |
| WO-1988004659-A2 | NOVEL CC-1065 ANALOGS | THE UPJOHN COMPANY (US) | 1988-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | EPHX2 1247/4885RAB9A 1245/4885NPC1 1992/4885 |
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | SLCO2B1, SLCO1B1, CYP21A2 | EPHX2 216/4885RAB9A 2835/4885NPC1 1069/4885 |
| US-20230227409-A1 | QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2B, MAT2A, MAT1A | EPHX2 2260/4885RAB9A 953/4885NPC1 2783/4885 |
| US-20200207735-A1 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | EPHX2 2262/4885RAB9A 3396/4885NPC1 1469/4885 |
| US-10556889-B1 | Salvinorin derivatives | OPRD1, OPRK1, OPRL1 | EPHX2 3131/4885RAB9A 1009/4885NPC1 1602/4885 |
| US-20160272581-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | FPR2, FPR1, FPR3 | EPHX2 2940/4885RAB9A 4721/4885NPC1 1890/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | EPHX2 801/4885RAB9A 4041/4885NPC1 187/4885 |
| US-11008301-B2 | Piperidinone formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | EPHX2 2262/4885RAB9A 3396/4885NPC1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.